Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types
This study underscores the potential risks associated with the concomitant use of PPIs and ICIs in cancer treatment. The findings suggest that careful consideration is necessary when prescribing PPIs to patients undergoing ICI therapy.
Authors
- Jing Zhang (ORCID: https://orcid.org/0000-0002-0313-6857)
- Richard Alweis (ORCID: https://orcid.org/0000-0002-4747-8066)
- Kaiwen Zhu (ORCID: https://orcid.org/0000-0002-1734-2512)
- Asim Mushtaq (ORCID: https://orcid.org/0000-0003-2592-1562)
- Harkarandeep Singh (ORCID: https://orcid.org/0009-0007-5711-7348)
- Mariam Mostafa (ORCID: https://orcid.org/0000-0002-3140-3991)
- Patrick Okolo (ORCID: https://orcid.org/0000-0003-0928-7303)
- Umer Farooq (ORCID: https://orcid.org/0000-0001-8272-0172)
- Ebubekir Daglilar (ORCID: https://orcid.org/0000-0003-0622-1704)
Institutions
- Charleston Area Medical Center (US)
- Unity Health System (US)
- Rochester General Hospital (US)
- Saint Louis University (US)
- Carilion Clinic (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-10-16
- DOI
- https://doi.org/10.6004/jnccn.2025.7070
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05